Literature DB >> 12560215

Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.

Gina Mundschau1, Sandeep Gurbuxani, Alan S Gamis, Marianne E Greene, Robert J Arceci, John D Crispino.   

Abstract

As many as 10% of infants with Down syndrome (DS) present with transient myeloproliferative disorder (TMD) at or shortly after birth. TMD is characterized by an abundance of blasts within the peripheral blood and liver, and notably undergoes spontaneous remission in the majority of cases. TMD may be a precursor to acute megakaryoblastic leukemia (AMKL), with an estimated 30% of TMD patients developing AMKL within 3 years. We recently reported that mutations in the transcription factor GATA1 are associated with DS-AMKL. To determine whether the acquisition of GATA1 mutations is a late event restricted to acute leukemia, we analyzed GATA1 in DNA from TMD patients. Here we report that GATA1 is mutated in the TMD blasts from every infant examined. These results demonstrate that GATA1 is likely to play a critical role in the etiology of TMD, and mutagenesis of GATA1 represents a very early event in DS myeloid leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12560215     DOI: 10.1182/blood-2002-12-3904

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

Review 1.  GATA transcription factors in hematologic disease.

Authors:  Alan B Cantor
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

2.  Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.

Authors:  Marius Flasinski; Kira Scheibke; Martin Zimmermann; Ursula Creutzig; Katarina Reinhardt; Femke Verwer; Valerie de Haas; Vincent H J van der Velden; Christine von Neuhoff; C Michel Zwaan; Dirk Reinhardt; Jan-Henning Klusmann
Journal:  Blood Adv       Date:  2018-07-10

Review 3.  GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.

Authors:  Te Ling; John D Crispino; Maria Zingariello; Fabrizio Martelli; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2018-02-19       Impact factor: 2.929

4.  GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.

Authors:  Su Han Lum; Soo Sin Choong; Shekhar Krishnan; Zulqarnain Mohamed; Hany Ariffin
Journal:  Singapore Med J       Date:  2016-06       Impact factor: 1.858

5.  Global transcriptome and chromatin occupancy analysis reveal the short isoform of GATA1 is deficient for erythroid specification and gene expression.

Authors:  Timothy M Chlon; Maureen McNulty; Benjamin Goldenson; Alexander Rosinski; John D Crispino
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

Review 6.  Malignancy in children with trisomy 21.

Authors:  Karen R Rabin; James A Whitlock
Journal:  Oncologist       Date:  2009-01-28

7.  Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.

Authors:  Hirokazu Kanegane; Sayaka Watanabe; Keiko Nomura; Gang Xu; Etsuro Ito; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

8.  The role of microRNAs in acute myeloid leukemia.

Authors:  R Katherine Hyde; P Paul Liu
Journal:  F1000 Biol Rep       Date:  2010-11-24

9.  Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder.

Authors:  Yehudit Birger; Liat Goldberg; Timothy M Chlon; Benjamin Goldenson; Inna Muler; Ginette Schiby; Jasmin Jacob-Hirsch; Gideon Rechavi; John D Crispino; Shai Izraeli
Journal:  Blood       Date:  2013-05-29       Impact factor: 22.113

10.  GATA-2 reinforces megakaryocyte development in the absence of GATA-1.

Authors:  Zan Huang; Louis C Dore; Zhe Li; Stuart H Orkin; Gang Feng; Simon Lin; John D Crispino
Journal:  Mol Cell Biol       Date:  2009-07-20       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.